Table 2.
Lymphoma Characteristics.
| Characteristic | DLBCL (n = 39) | Follicular Lymphoma (n = 62) | Hodgkin Lymphoma (n = 19) | Other Aggressive Lymphomas (n = 27) | Other Indolent Lymphomas (n = 30) |
|---|---|---|---|---|---|
| Median age (median [IQR]) | 70 (62-78) | 68 (51-76) | 58 (44-71) | 72 (61-76) | 76 (60-82) |
| Male (n [%]) | 26 (66.7) | 29 (46.8) | 12 (63.2) | 16 (59.3) | 16 (53.3) |
| Risk stratificationa (n [%]) | |||||
| Low risk | 6/33 (18.2) | 18/55 (32.7) | 3/15 (20) | 4/21 (19) | 10/19 (52.6) |
| Intermediate | 10/33 (30.3) | 17/55 (30.9) | 8/15 (26.6) | 7/21 (33.3) | 7/19 (36.8) |
| High risk | 17/33 (51.5) | 20/55 (36.4) | 4/15 (53.3) | 10/21 (47.6) | 2/19 (10.5) |
| Active treatmentb | 21/39 (53.8) | 31/62 (50) | 10/19 (52.6) | 17/27 (63) | 9/30 (30) |
| Lines of treatment (n [%]) | |||||
| 0 | 7/38 (18.4) | 6/61 (9.8) | 0/19 (0) | 3/26 (11.5) | 5/29 (17.2) |
| 1 | 23/38 (60.5) | 40/61 (65.6) | 8/19 (42.1) | 12/26 (46.2) | 14/29 (48.3) |
| 2 | 5/38 (13.2) | 9/61 (14.8) | 5/19 (26.3) | 4/26 (15.4) | 8/29 (27.6) |
| 3 | 2/38 (5.3) | 3/61 (4.9) | 2/19 (10.5) | 7/26 (26.9) | 2/29 (6.9) |
| ≥4 | 1/38 (2.6) | 3/61 (4.9) | 4/19 (21.1) | 0/26 (0) | 0/29 (0) |
| Therapeutics (n [%]) | |||||
| CD20-chemotherapyc | 27/33 (81.8) | 22/54 (40.7) | 0 (0) | 5/22 (22.7) | 4/24 (16.7) |
| CD20-bendamustine | 2/33 (6.1) | 7/54 (13) | 0 (0) | 6/22 (27.3) | 5/24 (20.8) |
| Chemotherapy | 4/33 (12.1) | 4/54 (7.4) | 12/19 (63.2) | 8/22 (36.4) | 5/24 (20.8) |
| Molecular targets | 0 (0) | 1/54 (1.9) | 0 (0) | 1/22 (4.5) | 1/24 (4.2) |
| Immunotherapyd | 0 (0) | 20/54 (37) | 7/19 (36.8) | 2/22 (9.1) | 9/24 (37.5) |
| Responsee (n [%]) | |||||
| Complete response | 14/38 (36.8) | 34/61 | 12/19 | 12/27 | 11/29 |
| Partial response | 2/38 (5.3) | 9/61 | 2/19 | 5/27 | 9/29 |
| Progression | 8/38 (21.1) | 8/61 | 5/19 | 6/27 | 2/29 |
| Not valuable | 14/38 (36.8) | 10/61 | 0/19 | 4/27 | 7/29 |
| Active diseasef (n [%]) | 10/24 (41.7) | 17/51 (33.3) | 7/19 (36.8) | 11/23 (47.8) | 11/22 (50) |
| Admission (n [%]) | 35 (89.7) | 51 (82.3) | 14/18 (77.8) | 24/26 (92.3) | 27 (90) |
| ICU admission (n [%]) | |||||
| Yes | 4 (10.3) | 5 (8.1) | 4 (21.1) | 1 (3.7) | 2 (6.7) |
| Not needed | 18 (46.2) | 44 (71) | 11 (57.9) | 18 (66.7) | 19 (63.3) |
| Dismissed | 17 (43.6) | 13 (21) | 4 (21.1) | 8 (29.6) | 9 (30) |
| Death (n [%]) | 19 (48.7) | 15 (24.2) | 7 (36.8) | 10 (37) | 10 (33.3) |
aRisk stratification at diagnosis.
bLymphoma treatment within the 3 previous months.
cCD20-chemotherapy includes RCHOP, R-CVP, R-ESHAP, or R-GemOx.
dAnti-CD20: 31 patients; brentuximab: 3 patients; nivolumab: 4 patients.
eAccording to Lugano response criteria.
fPartial response or progression.
DLBCL = diffuse large B cell lymphoma; ICU = intensive care unit; IQR = interquartile range; R-CHOP = cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CVP = cyclophosphamide, vincristine, prednisolone; R-ESHAP = etoposide, methylprednisolone, high dose cytarabine, and cisplatin; R-GemOx = gemcitabine and oxaliplatin.